Back to search results
NCT06885424

A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products

Enrolling by Invitation
Not specifiedAges 18+Observational
A2 Biotherapeutics Inc.
~400 participants
Updated 2026-05-20 on ClinicalTrials.gov
What's tested:No additional intervention administered in this long term follow-up study

At a glance

Recruiting sites
0 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Long-term safety of previous A2 Bio GT treatment
Measured over 15 years post treatment with A2 Bio GT product

Conditions

Solid Tumor Cancer
Solid Tumor, Unspecified, Adult
Colorectal Carcinoma
Colorectal Carcinoma (CRC)
Non Small Cell Lung Cancer
Small Cell Lung Cancer ( SCLC )
Pancreatic Cancer
NSCLC
Mesothelioma
Ovarian Cancer
Ovarian Carcinoma
Head and Neck (HNSCC)
Head and Neck Cancer
Renal Cell Carcinoma (Kidney Cancer)
Triple Negative Breast Cancer (TNBC)

Explore related trials

Colorectal CarcinomaLung Non-Small Cell CarcinomaLung Small Cell CarcinomaMalignant Head and Neck NeoplasmMalignant Ovarian NeoplasmMesothelial NeoplasmPancreatic CarcinomaRenal Cell CarcinomaSolid NeoplasmTriple-negative breast cancer

Where it's being run

3 sites across 3 states
Arizona1
Minnesota1
New York1

Study leadership

  • Eric Ng, MD · STUDY_DIRECTOR · A2 Biotherapeutics

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Long-term safety of previous A2 Bio GT treatment15 years post treatment with A2 Bio GT product

    Long-term safety of previous A2 Bio GT treatment as determined by incidence of adverse events (AEs)